3 / 13
Virology Research Journal
|
Volume 2
Page 23
Note:
allied
academies
IMMUNOLOGY AND CELL BIOLOGY
BACTERIOLOGY AND INFECTIOUS DISEASES
&
Global Summit on
Global Congress on
J u n e 2 5 - 2 6 , 2 0 1 8 | A m s t e r d a m , N e t h e r l a n d s
Joint Event on
SITE ATTACHMENT INHIBITION
THERAPEUTICS: DEALING WITH
ASSOCIATION AND CAUSATION
ISSUES
Simon Raymond
Alumnus Melbourne University, Australia
T
his talk highlights that site attachment inhibition (therapeutics involving
the negation of cellular attachment, or entry/transfer, by the pathogen)
is intended to consist of both: Treatment of established infections; and new
generation immunization programs (preventative treatment). New generation
immunization programs, based on prenatal stem cell therapy in the prenatal
period and earlier spanning back to spermatogenesis and oogenesis, is
intended to involve gene mutagenesis and knockout. Validation for likely
success includes inherited mutations mentioned in the references noted that
provide resultant resistance (immunity) to the stated infections including HIV
andMalaria. Association and causation issues need to be dealt with given that
even the known CCR5 mutation has not been completely confirmed as direct/
causative of the resultant resistance/immunity. A discussion with regards to
prenatal and germline stem cell therapy, in addition to CRISPR and CRISPR-
Cas9 is presented in the below link to the USNIH library. It is not up to date with
“site attachment inhibition” therapeutics, however it does provide a general
discussion on the above stated topics broadly. In brief, using technologies
including those above would allow comparison between cells in which entry
of the pathogen is occurring to those in which entry of the pathogen is not
occurring (or, not able to) and through analysis of the genetics of the human
cellular biology used by the pathogen to gain cellular attachment (or, transfer
and entry), the genes to be targeted in mutagenesis and knockout can be
analysed. NB: The pathogen machinery also is to be analysed. In summary,
this presentation presents new content with regards to site attachment
inhibition therapeutics. Site attachment inhibition therapeutics is intended to
be applicable to all infections broadly. The next conference presentations will
cover issues surrounding antimicrobial resistance.
Simon Raymond is a Consultant who special-
ised in Medical and Scientific Research and an
Alumnus of Melbourne University (Rank of Num-
ber 1 in Australia and Number 33 in the World).
He has worked as a Reviewer for the respected
Medical Journal of Australia
, has received invita-
tions internationally to review from prestigious
medical journals including
Journal of American
Medical Association
network. He has received
award in recognition of his research by Royal
Australasian College of Surgeons (PSC, 2006)
and invited to conferences internationally as
an official Delegate and Researcher, including
that in USA and China. He has worked as the
Principle Researcher in the highest-powered
form of medical trial—Randomised Controlled
Trial (RCT). He is also a Member of the Gold-
en Key International Society for honoured and
outstanding academics and has been cited as a
notable global leader.
simonraymondcontact@gmail.comBIOGRAPHY
Simon Raymond, Virol Res J 2018, Volume 2